The Hidden Fat… How Mounjaro and Wegovy are Your Secret Weapons.
For many, the weight loss journey is focused on what’s visible - the stubborn fat beneath the skin known as subcutaneous fat. But lurking deeper within the abdominal cavity, wrapped around vital organs like the liver and intestines, is a far more dangerous form of fat: visceral fat. This "active fat" is a metabolic disruptor, releasing inflammatory chemicals that significantly increase the risk of heart disease, type 2 diabetes, stroke, and certain cancers, even in individuals who are not visibly overweight. The good news is that new-generation weight loss medications like Mounjaro and Wegovy are proving remarkably effective at targeting and reducing this harmful internal fat.
Mounjaro and Wegovy: Beyond simple weight loss
Mounjaro (tirzepatide) and Wegovy (semaglutide) have gained significant attention for their ability to promote substantial overall weight loss. But their benefits run deeper than the number on the scale, specifically in how they influence where the body sheds fat. In clinical trials, both drugs have demonstrated a preferential reduction of visceral fat over subcutaneous fat, leading to improved waist measurements and significant health benefits. This is a crucial distinction, as it addresses the core metabolic issues associated with excess visceral fat.
The science behind the fat loss
Both medications work by mimicking gut hormones known as incretins, which regulate appetite and blood sugar. This biological mimicry is the driving force behind their effectiveness, though with a key difference. Wegovy's active ingredient, semaglutide, mimics a single incretin hormone, GLP-1, to increase feelings of fullness, reduce hunger, and improve insulin sensitivity. By reducing overall calorie intake, the body is prompted to draw energy from fat stores, including the dangerous visceral fat.
Mounjaro, on the other hand, is a dual agonist that mimics both GLP-1 and another incretin hormone, GIP. This dual-action approach enhances its effects on appetite control, blood sugar regulation, and fat metabolism, leading to even greater visceral fat reduction. Clinical studies have shown that participants on Mounjaro experience not only more overall weight loss than those on Wegovy but also a more significant reduction in waist circumference, which is a strong indicator of visceral fat loss.
Lifestyle changes amplify the results
While these medications are powerful tools, they are not magic pills. The most successful and sustainable visceral fat reduction occurs when Mounjaro or Wegovy is combined with healthy lifestyle changes. Incorporating regular physical activity, especially moderate- to high-intensity aerobic exercise, is particularly effective at reducing visceral fat. A balanced diet rich in whole foods, fibre, and lean protein, while limiting refined carbs and sugar, also plays a critical role. Getting sufficient sleep and managing stress levels are further key components, as they help regulate hormones that influence fat storage. By supporting these powerful medical treatments with consistent healthy habits, individuals can maximise the benefits and achieve lasting improvements in their metabolic health.
This is for informational purposes only. For medical advice pertaining to your personal treatment please consult your Mova Medical Professional.
Always follow the instructions that come with your medication and if in any doubt about your treatment contact Mova Medical Immediately.